From next-generation medications to groundbreaking gene therapies and nonsurgical procedures, explore the pipeline of ...

If your oHCM symptoms are returning or your energy is flagging, your treatment plan may need an update. Here's how to talk to ...

Robert Blum and Fady Malik, M.D., Ph.D, have been with Cytokinetics since its inception nearly three decades ago. | ...

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten improved left ventricular hypertrophy, decreased measures of heart stiffness and restored normal ...

BMS's efforts to expand the label of its drug into the non-obstructive setting – a milder form of the disease in which there ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.

Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and ...

Topline results announced today show gains in KCCQ and peak oxygen consumption—the full dataset is coming soon.